Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...

The appointment comes at a time when Pfizer is facing pressure from activist investor Starboard, which has criticized its ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Chris Boshoff will take on the role of chief scientific officer starting Jan 1 & oversee all functions of research & development across all therapeutic area ...

and Paxlovid brands. Pfizer also provides medicines and vaccines in various therapeutic areas, such as: Pneumococcal disease, ...

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...

Pfizer (NYSE:PFE – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday. A number of other analysts also recently ...

With family gatherings for the holidays approaching along with the beginning of the ski season, this is the time for respiratory-illness ...